newsfilter
← Latest News
Business Wire·

Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test

Real-Time Variant Tracker™ supplemental results track resistance and therapeutically targetable variants as cancer biology evolves. Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today